Sequential Use of Anaplastic Lymphoma Kinase Inhibitors in Japanese Patients WithALK-Rearranged Non–Small-Cell Lung Cancer: A Retrospective Analysis


    loading  Checking for direct PDF access through Ovid

Abstract

BackgroundSecond-generation anaplastic lymphoma kinase (ALK) inhibitors, such as alectinib and ceritinib, have recently been approved for treatment of ALK-rearranged non–small-cell lung cancer (NSCLC). An optimal strategy for using 2 or more ALK inhibitors has not been established. We sought to investigate the clinical impact of sequential use of ALK inhibitors on these tumors in clinical practice.Patients and MethodsPatients with ALK-rearranged NSCLC treated from May 2010 to January 2016 at the National Cancer Center Hospital were identified, and their outcomes were evaluated retrospectively.ResultsFifty-nine patients with ALK-rearranged NSCLC had been treated and 37 cases were assessable. Twenty-six received crizotinib, 21 received alectinib, and 13 (35.1%) received crizotinib followed by alectinib. Response rates and median progression-free survival (PFS) on crizotinib and alectinib (after crizotinib failure) were 53.8% (95% confidence interval [CI], 26.7%-80.9%) and 38.4% (95% CI, 12.0%-64.9%), and 10.7 (95% CI, 5.3-14.7) months and 16.6 (95% CI, 2.9-not calculable), respectively. The median PFS of patients on sequential therapy was 35.2 months (95% CI, 12.7 months-not calculable). The 5-year survival rate of ALK-rearranged patients who received 2 sequential ALK inhibitors from diagnosis was 77.8% (95% CI, 36.5%-94.0%).ConclusionThe combined PFS and 5-year survival rates in patients who received sequential ALK inhibitors were encouraging. Making full use of multiple ALK inhibitors might be important to prolonging survival in patients with ALK-rearranged NSCLC.Micro-AbstractSequential anaplastic lymphoma kinase (ALK) inhibitors for ALK-rearranged non–small-cell lung cancer (NSCLC) in Japanese patients were retrospectively reviewed. Thirteen patients received crizotinib followed by alectinib. The combined median progression-free survival and 5-year survival rates of patients who received sequential ALK inhibitors were 35.2 months and 77.8%. Making full use of multiple ALK inhibitors might be important to prolonging survival in patients with ALK-rearranged NSCLC.

    loading  Loading Related Articles